NAOMI M. KANOF LECTURE

Targeting the Epigenome in Cutaneous and Disseminated Malignancies

Thursday, April 27, 2017  9:30 am – 10:00 am  Oregon Ballroom 201-202

Introduction by:  Paul Nghiem, MD/PhD

James Bradner, MD
Novartis Institutes of BioMedical Research
Cambridge, Massachusetts

James (Jay) E. Bradner, MD is President of the Novartis Institutes for BioMedical Research (NIBR) and a member of the Executive Committee of Novartis. Prior to joining Novartis Dr. Bradner served on the research faculty of Harvard Medical School and as an attending physician in stem cell transplantation within the Department of Medical Oncology at the Dana-Farber Cancer Institute. The research focus of the Bradner laboratory has been the study of BET bromodomain proteins and their function in gene control, innovating chemical probes and investigational drugs to study and treat cancer. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 130 scientific publications and 30 United States patent applications. Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School. He completed residency in Medicine at Brigham & Women’s Hospital, fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute and postdoctoral training in chemistry and chemical biology at Harvard University (Prof. Stuart Schreiber). He is the recipient of many honorific awards and was elected into the American Society of Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

LECTURESHIP HISTORY

Established in 1988, this award was established to honor the memory of Naomi Kanof, MD. The Naomi M. Kanof Lectureship honors an individual making significant contributions to the improvement of health through clinical research. Clinical research is broadly defined as any scientific endeavor with a direct application to improving the prevention, diagnosis or treatment of clinical disease. This investigational work can be based in the laboratory and should be implemented or just ready to be implemented in clinical practice.